Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Study underscores the direct vascular effects of this class of drugs, researchers say AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

This between-group difference produced an estimated treatment ratio of 1.13 for semaglutide (95% CI 1.06-1.21), corresponding, in absolute terms, to a median 26.4-meter improvement in maximum walking ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients with other clinical manifestations of atherosclerotic cardiovascular ...